| Literature DB >> 30134841 |
C Almiñana1,2, G Tsikis3, V Labas3,4, R Uzbekov5,6, J C da Silveira7, S Bauersachs8, P Mermillod3.
Abstract
BACKGROUND: The success of early reproductive events depends on an appropriate communication between gametes/embryos and the oviduct. Extracellular vesicles (EVs) contained in oviductal secretions have been suggested as new players in mediating this crucial cross-talk by transferring their cargo (proteins, mRNA and small ncRNA) from cell to cell. However, little is known about the oviductal EVs (oEVS) composition and their implications in the reproductive success. The aim of the study was to determine the oEVs content at protein, mRNA and small RNA level and to examine whether the oEVs content is under the hormonal influence of the estrous cycle.Entities:
Keywords: Exosomes; Gamete/embryo-maternal interaction; Hormones; Microvesicles; Oviduct; Proteomics; RNA-sequencing
Mesh:
Substances:
Year: 2018 PMID: 30134841 PMCID: PMC6103977 DOI: 10.1186/s12864-018-4982-5
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Oviduct EVs characterization and quantification across the bovine estrous cycle. a Representative images of exosomes (blue arrows, 30–100 nm size) and microvesicles (red arrows > 100 nm size) across the different stages of the bovine estrous cycle (Stage 1, Stage 2, Stage 3 and Stage 4) by TEM. b Histograms showing the size distribution of oEVs across the estrous cycle. A batch of 12 samples containing 3 replicates/stage were analyzed using TEM and ImageJ software. Comparison between populations of exosomes and microvesicles for each stage were performed (*P < 0.05; **P < 0.01, T-test. c Western blotting characterization of bovine oEVs at all 4 stages analyzed for known exosomal protein markers. A pool of samples containing 3 biological replicates at the 4 different stages analyzed was used, showing oEVs from all 4 stages were positive for HSP70 and ANAX1.). d Bovine oEVs size average and concentration was measured by Nanosight analysis from a different batch of 12 samples (3 replicates /stage)
Fig. 2Comparative analysis of the oviduct EVs mRNA content across the bovine estrous cycle. a Principal Component analysis (PCA) on mRNA oviduct EVs content at 4 different stages of the estrous cycle (S1 in yellow; S2 in red, S3 in green and S4 in blue). b Venn Diagram demonstrating relations among differential transcripts (DT) for selected comparisons during the estrous cycle. Data were analyzed with a cut-off FDR < 0.001. c Dendrogram representing results of unsupervised hierarchical clustering (HCL) created with Pearson correlation coefficient by MeV. Rows indicate single differential transcripts (DT), while columns represent individual samples collected at different stages of the estrous cycle. Mean-centered expression values (log2 counts per million of sample – mean of log2 counts per million of all samples) for the samples of the 4 stages are shown. Color scale is from −4 (blue, lower than mean) to 4 (red, higher than mean)
DAVID functional annotation clusters for top 500 most abundant mRNA identified in oEVs
| Most descriptive categories of DAVID functional annotation clusters groups by similar GO terms | #mRNA1 | Score2 |
|---|---|---|
| GO Group 1: Protein translation and transport | 236 | 63 |
| protein transport (145, 2.8)3, translation (129, 7.3), ribosome (87, 11.4), protein targeting to ER (81, 28.4), nuclear transport (29, 2.2), regulation of protein localization (40, 1.5) | ||
| GO Group 2: Extracellular vesicles | 254 | 59.4 |
| extracellular exosome (253, 3), extracellular vesicle (253, 3), phagocytosis (13, 1.7) | ||
| GO Group 3: Gene expression | 314 | 46.5 |
| RNA binding (203, 4.4), gene expression (244, 1.7), negative regulation of metabolic process (109, 1.6), negative regulation of transcription, DNA-templated (42, 1.4) | ||
| GO Group 4: Cell adhesion | 139 | 40.5 |
| adherens junction (112, 5.3), focal adhesion (77, 6.5), cadherin binding (51, 5.9) | ||
| GO Group 5: Mitochondrion/oxidation-reduction | 131 | 7.4 |
| mitochondrion (86, 1.7), generation of precursor metabolites and energy (37, 3.6), oxidation-reduction process (49, 1.8), ATP metabolic process (30, 4.5), oxidative phosphorylation (23, 4.2) | ||
| GO Group 6: Apoptosis | 87 | 6 |
| programmed cell death (87, 1.7), apoptotic signaling pathway (40, 2.5), apoptotic mitochondrial changes (10, 3.1) | ||
| GO Group 7: ATPase/GTPase | 54 | 6 |
| nucleoside-triphosphatase activity (51, 2.3), ATPase activity (23, 1.9), GTPase activity (21, 3.2), GTP binding (22, 2.0) | ||
| GO Group 8: Response to stress | 172 | 5 |
| cellular response to stress (78, 1.6), response to oxidative stress (28, 2.6), antioxidant activity (11, 4.9), reactive oxygen species metabolic process (16, 2.6), regulation of response to DNA damage stimulus (10, 2.3) | ||
| GO Group 9: RNA processing/transport | 42 | 3.3 |
| RNA splicing (29, 2.6), mRNA processing (25, 1.9), spliceosomal complex (14, 2.6), RNA localization (14, 2.4), nuclear export (10, 2.0) | ||
| GO Group 10: Immune response, proteolysis | 112 | 3.2 |
| immune response (59, 1.4), regulation of proteolysis (40, 2.1), regulation of mRNA stability (23, 4.8), regulation of cytokine production (26, 1.6), platelet activation (13, 2.9), regulation of peptidase activity (23, 2.1) | ||
| GO Group 11: Cell cycle | 64 | 2.9 |
| mitotic cell cycle (45, 1.7), regulation of cell cycle (40, 1.5) | ||
| GO Group 12: Cytoskeleton | 71 | 2.7 |
| cytoskeleton (50, 1.9), microtubule (21, 1.7), cytoskeleton organization (51, 1.6), actin cytoskeleton organization (28, 1.8), actin filament organization (18, 2.0) | ||
| GO Group 13: Signal transduction, phosphorylation | 192 | 2.6 |
| regulation of protein metabolic process (118, 1.7), signal transduction by protein phosphorylation (38, 1.6), intracellular signal transduction (88, 1.2), phosphorylation (75, 1.2), phosphorus metabolic process (105, 1.2) | ||
| GO Group 14: Chromatin | 23 | 2.6 |
| chromatin DNA binding (11, 3.8), protein-DNA complex assembly (15, 2.3), chromatin assembly (9, 2.0) | ||
| GO Group 15: Development | 41 | 2.3 |
| gland development (22, 1.9), reproductive system development (19, 1.6), developmental process involved in reproduction (25, 1.4) | ||
| GO Group 16: Response to hormones, growth factors, nutrients | 80 | 2.2 |
| response to organic cyclic compound (42, 1.7), response to steroid hormone (20, 1.9), response to nutrient levels (19, 1.7), response to growth factor (28, 1.6), response to glucocorticoid (12, 3.1), response to cAMP (8, 3.0) | ||
| GO Group 17: Cell organization | 82 | 1.8 |
| regulation of organelle organization (47, 1.5), regulation of cellular component organization (76, 1.2), cell leading edge (20, 1.9) | ||
| GO Group 18: Others | 68 | 2.6 |
| energy reserve metabolic process (11, 4.3), glycogen metabolic process (10, 4.6), isomerase activity (13, 2.8), muscle contraction (17, 1.9), organic acid metabolic process (37, 1.5) |
Table shows DAVID functional annotation clusters with a score ≥ 1.3. 1number of unique mRNA in each GO group;2enrichment score (geometric mean of member’s p-values of the corresponding annotation cluster in -log10 scale) of the annotation cluster; 3in brackets: number of genes and fold enrichment for the functional term
Fig. 3Network of enriched GO terms associated to up and downregulated transcripts during stage 1 (S1). Comparative enrichment analysis of GO terms associated to transcripts up or downregulated in oviduct EVs at stage 1 of the estrous cycle compared to the rest of the stages (S2, S3, S4). The network shows enriched GO terms (biological process, a molecular function and cellular component) and pathways specifically overrepresented for the up and downregulated transcripts
Fig. 4Comparative analysis of the oviduct EVs protein content across the bovine estrous cycle. A) Principal Component analysis (PCA) on protein oviduct EVs content at 4 different stages of the estrus cycle (S1 in dark blue; S2 in light blue; S3 in brown and S4 in red) based on normalized weighted spectra data. B) Venn Diagram demonstrating relations among differential proteins (DP) for selected comparisons during the estrous cycle. Data were analyzed with cut-off FDR < 0.001. C) Dendrogram representing results of unsupervised hierarchical clustering (HCL) by MeV. Mean-centered expression values (log2 expression value of sample – mean of log2 expression values of all samples) for the samples of the 4 stages are shown. Rows indicate single DP, while columns represent different stages of the estrous cycle. Clusters of proteins strongly differentially regulated among stages are pointed with doted squares in HCL figure. These clusters of proteins were used for functional analysis and GO enriched terms are shown in proteins network in Fig. 5
Fig. 5Network of enriched GO terms associated to up and downregulated proteins during stage 1–4. Comparative enrichment analysis of GO terms associated to clusters of differential proteins up or downregulated in oviduct EVs at 1–4 stages of the estrus cycle. The network shows the enriched GO terms (biological process, a molecular function and cellular component) and pathways specifically overrepresented for the different protein cluster lists showing differential expression across the estrous cycle. The 5 clusters of differential proteins used for building the network are represented in Fig. 4C
DAVID functional annotation clusters for all proteins identified in oEVs
| Most descriptive categories of DAVID functional annotation clusters groups by similar GO terms | # Proteins1 | Score2 |
|---|---|---|
| GO Group 1: Vesicle/exosome/secretion | 271 | 114.5 |
| extracellular exosome (263, 4.2)3, vesicle membrane (32, 2.8), exocytosis (30, 3.9), secretion (50, 2.4) | ||
| GO Group 2: Cell adhesion/junction | 141 | 49.9 |
| adherens junction (106, 6.9), cell-cell junction (61, 4.3) cell-cell adhesion (71, 3.2), cell junction organization (13, 2.7) | ||
| GO Group 3: Protein secretion/folding | 129 | 29.1 |
| protein targeting to ER (42, 21.1), protein folding (27, 6.2), Protein processing in endoplasmic reticulum (15, 2.8), regulation of secretion (23, 1.8) | ||
| GO Group 4: Gene expression | 168 | 21.1 |
| poly(A) RNA binding (102, 4.3), gene expression (137, 1.4), RNA biosynthetic process (87, 1.2) | ||
| GO Group 5: Wound healing/coagulation | 154 | 9.9 |
| regulation of body fluid levels (38, 4), coagulation (31, 4.5), wound healing (37, 3.6), platelet activation (21, 6.8), blood circulation (19, 5.8) | ||
| GO Group 6: Small molecule binding | 109 | 10.6 |
| nucleoside-triphosphatase activity (47, 3), small molecule binding (96, 1.9), ATP binding (57, 1.9), GTPase activity (22, 4.7) | ||
| GO Group 7: Signal transduction | 137 | 7 |
| posttranscriptional regulation of gene expression (38, 4,2), regulation of protein modification process (62, 2), protein phosphorylation (59, 1.7), regulation of cell communication (85, 1.5) | ||
| GO Group 8: Proteolysis/cell cycle | 89 | 6 |
| proteasome complex (14, 9.6), mitotic cell cycle (37, 3.2), proteolysis (57, 1.7), endopeptidase activity (21, 2.1) | ||
| GO Group 9: Cytoskeleton organization | 95 | 5.4 |
| cytoskeleton organization (45, 2.1), microtubule cytoskeleton (51, 2.1), contractile fiber (15, 3), actin filament organization (19, 3), Ras GTPase binding (13, 2.4) | ||
| GO Group 10: Apoptosis | 66 | 5.2 |
| programmed cell death (61, 1.7), intrinsic apoptotic signaling pathway (12, 2.3), negative regulation of intracellular signal transduction (16, 1.8) | ||
| GO Group 11: Protein stabilization/sperm-zona pellucida interaction | 21 | 4.9 |
| protein stabilization (18, 6.9), zona pellucida receptor complex (6, 30.1), binding of sperm to zona pellucida (7, 10.2), fertilization (10, 3.2) | ||
| GO Group 12: Carbohydrate derivative metabolism | 60 | 3.8 |
| carboxylic acid metabolic process (35, 2.2), NADH metabolic process (9, 12.7), nucleotide metabolic process (29, 2.3), carbohydrate metabolic process (25, 1.7) | ||
| GO Group 13: Protein biosynthesis | 19 | 3.7 |
| Protein biosynthesis (16, 6.7), tRNA aminoacylation (8, 7.9), translational elongation (9, 3.5) | ||
| GO Group 14: Cell motility | 52 | 3.4 |
| locomotion (52, 1.8), cell motility (47, 1.9), cell migration (42, 1.9) | ||
| GO Group 15: Oxidative stress | 24 | 3.4 |
| response to oxidative stress (20, 2.7), reactive oxygen species metabolic process (14, 3.3) | ||
| GO Group 16: Cell development | 62 | 3.1 |
| cell development (51, 1.4), epithelial cell differentiation (20, 1.9), establishment or maintenance of cell polarity (12, 3.7) | ||
| GO Group 17: Ion homeostasis | 67 | 2.2 |
| iron ion homeostasis (6, 4.4), homeostatic process (56, 1.8), ion homeostasis (22, 1.6), regulation of ion transport (21, 2.0) | ||
| GO Group 18: Others | 30 | 7.9 |
| Annexin (9, 40.7), calcium-dependent protein binding (13, 11.2), phospholipid binding (19, 2.7), high-density lipoprotein particle (4, 6.9), steroid binding (6, 3.4) |
Table shows DAVID functional annotation clusters with a score ≥ 1.3. 1number of unique proteins in each GO group;2highest enrichment score (geometric mean of member’s p-values of the corresponding annotation cluster in -log10 scale) of each group; 3in brackets: number of genes and fold enrichment for the functional term
Fig. 6RNA type distribution of the oviduct EVs small ncRNA content across the bovine estrous cycle. a Pie graph shows the percentage of sequences attributed to each RNA type among all ncRNAs identified by small RNA sequencing in oviduct EVs across the cycle (miRNAs, rRNA fragments, tRNA fragments, snRNA, snoRNA, and other ncRNAs). b Bar graph shows the percent of reads attributed to each RNA type per stage of cycle. c Bar graph shows the percent of reads attributed to each RNA type for each sample
Fig. 7Comparative analysis of the snRNA expression across the bovine estrous cycle. Principal Component analysis (PCA) on snRNA oviduct EVs content at 4 different stages of the estrous cycle (Stage 1: S1 in yellow; Stage 2: S2 in red, Stage 3: S3 in green and Stage 4: S4 in blue) for all snRNA identified. Five different replicates for each stage were analysed (represented by R1, R2, R3, R4 and R5) in the plot. PCA showed a partial separation between stage 1 and 2 (S1, S2) and stages 3 and 4 (S3, S4)
List of differential miRNAs among S3 vs S1 and S4 vs S1 (FDR < 0.1)
| Stage comparison | Regulation | |
|---|---|---|
| UP | DOWN | |
| S3 vs S1 |
|
|
|
|
| |
| bta-miR-92a |
| |
| bta-miR-423-3p | bta-miR-375 | |
| bta-miR-429 | ||
| S4 vs S1 |
|
|
|
|
| |
|
| Novel miRNA | |
|
| bta-miR-34b-3p | |
|
| ||
|
| ||
| bta-miR-30d | ||
| bta-miR-148a-3p | ||
| bta-miR-125b-2-5p | ||
All miRNA FDR < 0.1; miRNA FDR < 0.05 in bold
Selected miRNAs in oEVs in Stage 1 and 4 and associated pathways and target genes
| miRNAs | KEGG pathway | p-value | Examples Target Genes (Gene Symbol) |
|---|---|---|---|
| hsa-mir-10b-5p | Pyrimidine metabolism | 0.0214 | NME4,NME2,POLR2D,POLR2A,POLR1B,NME1,CMPK1 |
| hsa-miR-423-3p | Fatty acid biosynthesis | 0.0000 | FASN, ACACA |
| Fatty acid metabolism | 0.0000 | FASN, ACACA, ACOX3, FADS2 | |
| hsa-miR-449a | Carbon metabolism | 0.0286 | TKT,GAPDH,GOT1,H6PD,MDH2,RPIA,ENO1,ALDOA,ADH5 |
| HIF-1 signaling pathway | 0.0390 | NFKB1,GAPDH,LTBR,BCL2,ENO1,LDHA,PIK3CA,SLC2A1,MKNK2,ALDOA,SERPINE1 | |
| hsa-miR-375 | Hippo signaling pathway | 0.0000 | YAP1,YWHAG,CCND2,MOB1B,YWHAB,WWC1,AMOT,FZD8,MPP5,FZD4,DLG4, |
| Amino sugar and nucleotide sugar metabolism | 0.0390 | PGM2,CMAS,UXS1,UGP2,HK2 | |
| hsa-miR-24-3p | Fatty acid biosynthesis | 0.0000 | FASN,MCAT,ACACA |
| Vitamin B6 metabolism | 0.0001 | PDXK,PNPO,PHOSPHO2 | |
| Endocytosis | 0.0005 | RNF41,PSD4,CHMP7,VPS45,SMAD2,CBL,DNM2,FGFR3,VTA1,AGAP3,CAV1,AP2B1,N | |
| Hippo signaling pathway | 0.0014 | ACTB,GSK3B,FZD5,YWHAH,SMAD2,BTRC,APC,NF2,YWHAG,SMAD3,WWTR1,TGFB1, | |
| Bacterial invasion of epithelial cells | 0.0078 | ACTB,ITGB1,CBL,DNM2,PIK3CB,CAV1,PXN,BCAR1,CLTC,CD2AP,CAV2,CTTN,PTK2, | |
| TGF-beta signaling pathway | 0.0228 | SMAD2,ACVR1B,SMAD3,TGFB1,SKP1,MYC,EP300,IFNG,E2F4,CREBBP,TGFBR2,BMP4, | |
| Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 0.0343 | HS6ST2,NDST1,HS6ST1,EXTL3,HS2ST1,HS6ST3 | |
| DNA replication | 0.0343 | CNA,FEN1,MCM4,MCM5,MCM7,RNASEH1,PRIM1,POLA1 | |
| RNA degradation | 0.0423 | PDCP1A,CNOT6,TOB2,CNOT4,DDX6,HSPD1,EXOSC3,EXOSC1,BTG2,DCP2,RQCD1, | |
| hsa-miR-429 | Axon guidance | 0.0009 | PAK2,PPP3R1,RHOA,KRAS,PPP3CA,PTK2,CFL2,RAC1,LIMK1,EFNA1 |
| Fc gamma R-mediated phagocytosis | 0.0350 | CRKL,CRK,WASF3,PLCG1,CFL2,RAC1,LIMK1,ARF6 | |
| Steroid biosynthesis | 0.0000 | SC5D,MSMO1,DHCR24,LSS,FDFT1,LIPA | |
| Antigen processing and presentation | 0.0019 | B2M,IFI30,HSPA4,HSP90AA1,HLA-C,HLA-B,NFYA,PSME2,CANX,PDIA3,HSPA8, | |
| Progesterone-mediated oocyte maturation | 0.0039 | ADCY1,CCNB1,PGR,ADCY7,CCNA2,CDC25B,CPEB4,HSP90AA1,PDE3A,RAF1, | |
| Gap junction | 0.0346 | ADCY1,ADCY7,GNAS,MAP2K5,RAF1,TUBB,TUBB6,CDK1,KRAS,TUBA8,GNA11 | |
| hsa-miR-34b-3p | Glycosaminoglycan degradation | 0.0000 | GNS,IDS,GLB1 |
| hsa-miR-200b-3p | Ras signaling pathway | 0.0043 | KSR1,RASA2,SHC1,PAK2,ETS1,RALBP1,PLD1,RHOA,KRAS,PLCG1,REL,FLT1, |
| Neurotrophin signaling pathway | 0.0273 | CRKL,CRK,SHC1,FRS2,BCL2,RHOA,KRAS,RPS6KA5,PLCG1,JUN,KIDINS220 | |
| hsa-miR-92a-3p | Cell cycle | 0.0000 | GSK3B,PCNA,SMC1A,CCNB1,SMAD2,HDAC1,CCND2,DBF4,SMC3,CDKN1B, |
| Adherens junction | 0.0000 | ACTB,TGFBR1,WASL,SMAD2,IQGAP1,IGF1R,VCL,FYN,MLLT4,NLK,CDH1,S | |
| Thyroid hormone signaling pathway | 0.0011 | ACTB,GSK3B,PRKCA,MED13L,NRAS,RCAN1,PIK3CB,HDAC1,MED13,NOTCH2 | |
| FoxO signaling pathway | 0.0024 | IRS2,BRAF,STAT3,TGFBR1,CCNB1,SMAD2,NRAS,STK4,GABARAPL2,PIK3CB,SETD7 | |
| RNA transport | 0.0025 | SAP18,GEMIN6,NUP153,TGS1,NUP210,XPOT,EIF3B,ELAC2,RPP14,EIF2S3,RNPS1 | |
| p53 signaling pathway | 0.0045 | CCNB1,BID,THBS1,CCND2,CDK1,GADD45A,CDK6,CHEK1,ATM,CCND1,CCNE2,SHISA5 | |
| Signaling pathways regulating pluripotency of stem cells | 0.0178 | PCGF6,JARID2,TCF3,GSK3B,STAT3,KAT6A,SMAD2,NRAS,INHBB,PIK3CB,WNT5A,TBX3 | |
| Protein processing in endoplasmic reticulum | 0.0179 | HSPA1A,EIF2AK1,RAD23B,ERO1L,NPLOC4,SEL1L,UBQLN1,SEC23A,SSR2,P4HB,XBP1 | |
| Notch signaling pathway | 0.0190 | HDAC1,CTBP1,DTX2,NOTCH2,HES1,HDAC2,KAT2A,RBPJ,KAT2B,EP300,CREBBP,MAML1 | |
| Spliceosome | 0.0210 | HSPA1A,LSM7,DDX23,SRSF5,PPIL1,U2SURP,EFTUD2,SF3B1,U2AF2,SNRPE,SF3A3 | |
| MAPK signaling pathway | 0.0210 | BRAF,DUSP4,PRKCA,HSPA1A,TGFBR1,NFKB1,NRAS,CRKL,STK4,ELK4,CRK,DUSP6 | |
| Wnt signaling pathway | 0.0386 | GSK3B,PRKCA,LRP6,TBL1X,BTRC,VANGL1,WNT5A,CTBP1,CCND2,FZD6,AXIN1,SKP1 | |
| Focal adhesion | 0.0393 | BRAF,ACTB,GSK3B,PRKCA,ITGB8,CRKL,CRK,THBS1,ITGA8,PIK3CB,PIP5K1C,PPP1CC | |
| Biosynthesis of amino acids | 0.0473 | TKT,BCAT2,GAPDH,PHGDH,TALDO1,PKM,SHMT2,BCAT1,MTR,ENO1,GOT2,PFKM,ASS1 | |
| hsa-miR-151a-3p | Biosynthesis of unsaturated fatty acids | 0.0000 | PTPLB,ELOVL5,SCD |
| Fatty acid metabolism | 0.0003 | HADH, PTPLB,ACACA,SCD,ELOVL5 | |
| hsa-miR-30d-5p | Mucin type O-Glycan biosynthesis | 0.0000 | GALNT7,B4GALT5,ST3GAL1,GALNT6,GCNT3,GALNT1,GALNT3,GALNT2 |
| Oocyte meiosis | 0.0000 | FBXO5,CAMK2D,PGR,BTRC,CALM1,CPEB4,YWHAG,PPP1CC,PPP3R1 | |
| Ubiquitin mediated proteolysis | 0.0000 | UBE2R2,BTRC,FBXW7,TRIM37,CUL2,NEDD4L,FZR1,PRPF19,MAP3K1 | |
| mRNA surveillance pathway | 0.0317 | MSI2,SAP18,PPP2R3A,EIF4A3,HBS1L,PPP1CC,CPSF2,CPSF6,PAPOLA | |
| hsa-miR-125b-5p | ErbB signaling pathway | 0.0016 | PRKCA,ERBB2,NRAS,CRKL,CRK,PAK2,RAF1,CDKN1B,EIF4EBP1,ERBB3 |
| Regulation of actin cytoskeleton | 0.0135 | SSH2,EZR,NRAS,CRKL,CRK,PIP5K1C,PAK2,ARHGEF12,PPP1CC,ACTG1 |
Table shows selected miRNAs based on differential expression and high abundance in EVs in Stage 1 and Stage 4 and associated representative pathways and target genes
Fig. 8Selected miRNA and their associated pathways. Selected miRNAs based on differential expression and high abundance in EVs in Stage 1 and Stage 4 were used for clustering analysis based on the presence of interactions of target genes and pathways using DIANA-miRPath v3.0. Heatmap clustering of 13 miRNAs versus their associated pathways based on significance levels. Color scale from red (highest significance) to yellow (not significant)
Fig. 9Validation of Mass Spectrometry and miRNA analyses of bovine oEVs by Western immunoblotting and qPCR. a Western blot analysis confirmed MS results for 3 proteins associated with reproductive roles and showing differential abundance or not across the bovine estrus cycle: CD109, HSPA8 and MYH9. A pool of samples containing 3 biological replicates at the 4 different stages analyzed was used. b qPCR analysis confirmed miRNA-seq results for Mir-449a, which dysregulation has been associated with defective cilia in the oviduct and infertility. Mir-449a was more abundant in S1 compared to the rest of the stages (p < 0.05, T-test). A new batch of oEVs isolated from oviducts classified in the four stages of the estrous cycle (n = 12) was used. c Network of Mir-449a target genes and overrepresented functional categories
Fig. 10Overlap of all transcripts and proteins identified in oviduct EVs across the bovine estrus cycle. a Venn Diagram demonstrating the overlap among all transcripts and proteins identified in EVs; b Heatmap representing results of unsupervised hierarchical clustering (HCL) by MeV. Rows indicate single proteins and transcripts, while columns represent different stages of the estrous cycle for transcripts (TS1-TS4) and proteins (PS1-PS4) analyses. Expression values for proteins and transcripts were log2-transformed and scaled to have values in a similar numerical range. c Heatmap representing the 25 top most abundant proteins which were attributed to known exosomal proteins (Annexins, Heat Shock proteins) and proteins associated to reproductive roles (OVGP, HSPA8). d Heatmap showing the 25 top most abundant transcripts representing mainly mRNAs encoding different ribosomal proteins (RPS, RPL)